The primary objective of this study is to assess the 10-year overall survival (OS) of patients with different lymphoproliferative disorders. Secondary objectives include evaluating the comorbidities and fitness of patients and their impact on treatment choices and outcomes. Additionally, the study will examine the effectiveness of various therapeutic regimens, with a particular focus on new treatments, such as chemo-free protocols, targeted drugs, and cell therapies, in order to determine the best treatment sequence for refractory and relapsed cases.

The research will also investigate how clinical and biological factors influence disease progression or relapse. Another aim is to explore potential correlations between genotype, clinical phenotype, and outcomes, both at diagnosis and during various disease stages. The study will also assess the incidence of tumor lysis syndrome and other adverse events during treatment, considering how these factors might affect treatment discontinuations or dose reductions.

Another objective is to evaluate the outcomes of patients who are managed with a "watch and wait" approach. Long-term toxicities and the occurrence of secondary malignancies will also be studied, alongside the analysis of healthcare costs and the resources used in patient management.

Inclusion Criteria:

• Patients ≥ 18 years diagnosed with and/or treated for lymphoproliferative disorders.
• Prospective patients (or their or legal guardians) who have the ability to understand and be willing to sign a written informed consent document
• Retrospective patients who have signed the institutional document allowing the use of their data for research on their disease

Exclusion Criteria:

• Patients who are unable to understand informed consent document

Patients ≥ 18 years diagnosed with and/or treated for lymphoproliferative disorders.